Open AccessEfficacy and safety of peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus infection
Author(s) -
Dragan Delić
Publication year - 2006
Publication title -
medicinski pregled
Language(s) - English
Resource type - Journals
eISSN - 1820-7383
pISSN - 0025-8105
DOI - 10.2298/mpns0610415d
Subject(s) - medicine , ribavirin , cirrhosis , adverse effect , hepatocellular carcinoma , gastroenterology , peginterferon alfa 2a , hepatitis c , hepatitis c virus , population , immunology , virus , environmental health
Chronic hepatitis C remains a formidable threat to world health. Progression of chronic hepatitis C is associated with significant morbidity: cirrhosis, hepatic failure and hepatocellular carcinoma. The introduction of combined therapy with pegylated interferons and ribavirin has increased the sustained virologic response (SVR) in the much higher percentage than with previous treatment options, while the level of adverse effects has not changed significantely. The aim of this study was to assess the efficacy and safety of combined therapy (peginterferon alfa-2a + ribavirin) in Serbian population.